R O Silveira1, V Zanatto, J C Appolinário, F Kapczinski. 1. Laboratory of Experimental Psychiatry Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350, 90035-000, Porto Alegre, RS, Brazil. ricardoosilveira@terra.com.br
Abstract
BACKGROUND: The objective of this study was to evaluate the effectiveness and safety of reboxetine, a selective noradrenaline reuptake inhibitor, in the treatment of obese patients with binge eating disorder (BED). METHOD: Nine outpatients with BED and obesity received reboxetine 8 mg/day for 12 weeks. The number of days with binge eating episodes per week was considered the primary outcome measure. Body weight, body mass index (BMI), Binge Eating Scale (BES), Clinical Global Impression Severity (CGI-S) and the World Health Organization Quality of Life Assessment Scale (WHOQOL-BREF) scores were used as secondary outcome measures. Paired t-test with the last observation carried forward was used to analyze changes from baseline to endpoint. RESULTS: Five patients completed the study and showed a complete remission of BED. The mean binge days per week was significantly reduced from 4.6+/-1.8 to 0.2+/-0.6, at the end of the study (p=0.0002). Mean BES scores were decreased from 32.3+/-6.3 to 9.3+/-6.8 (p=0.0003). There was also a statistically significant decrease in BMI (from 36.5+/-4.48 to 35.06+/-4.49; p=0.01), and in CGI-S (from 5.1+/-0.9 to 1.4+/-1.01; p=0.0002). Quality of life, assessed using the WHOQOL-BREF was significantly improved on overall quality of life and general health (p=0.02) and on psychological (p=0.03) domain. No serious adverse events were observed. CONCLUSION: Reboxetine may be an effective and well-tolerated agent in the treatment of BED in obese patients.
BACKGROUND: The objective of this study was to evaluate the effectiveness and safety of reboxetine, a selective noradrenaline reuptake inhibitor, in the treatment of obesepatients with binge eating disorder (BED). METHOD: Nine outpatients with BED and obesity received reboxetine 8 mg/day for 12 weeks. The number of days with binge eating episodes per week was considered the primary outcome measure. Body weight, body mass index (BMI), Binge Eating Scale (BES), Clinical Global Impression Severity (CGI-S) and the World Health Organization Quality of Life Assessment Scale (WHOQOL-BREF) scores were used as secondary outcome measures. Paired t-test with the last observation carried forward was used to analyze changes from baseline to endpoint. RESULTS: Five patients completed the study and showed a complete remission of BED. The mean binge days per week was significantly reduced from 4.6+/-1.8 to 0.2+/-0.6, at the end of the study (p=0.0002). Mean BES scores were decreased from 32.3+/-6.3 to 9.3+/-6.8 (p=0.0003). There was also a statistically significant decrease in BMI (from 36.5+/-4.48 to 35.06+/-4.49; p=0.01), and in CGI-S (from 5.1+/-0.9 to 1.4+/-1.01; p=0.0002). Quality of life, assessed using the WHOQOL-BREF was significantly improved on overall quality of life and general health (p=0.02) and on psychological (p=0.03) domain. No serious adverse events were observed. CONCLUSION:Reboxetine may be an effective and well-tolerated agent in the treatment of BED in obesepatients.
Authors: Lesley M Arnold; Susan L McElroy; James I Hudson; Jeffrey A Welge; Aurora J Bennett; Paul E Keck Journal: J Clin Psychiatry Date: 2002-11 Impact factor: 4.384
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Shishuka Malhotra; Karen H King; Jeffrey A Welge; Lori Brusman-Lovins; Susan L McElroy Journal: J Clin Psychiatry Date: 2002-09 Impact factor: 4.384
Authors: Jose C Appolinario; Josué Bacaltchuk; Rosely Sichieri; Angelica M Claudino; Amelio Godoy-Matos; Christina Morgan; Maria T Zanella; Walmir Coutinho Journal: Arch Gen Psychiatry Date: 2003-11
Authors: Susan L McElroy; Lesley M Arnold; Nathan A Shapira; Paul E Keck; Norman R Rosenthal; M Rezaul Karim; Marc Kamin; James I Hudson Journal: Am J Psychiatry Date: 2003-02 Impact factor: 18.112
Authors: Tamás Ágh; Gábor Kovács; Dylan Supina; Manjiri Pawaskar; Barry K Herman; Zoltán Vokó; David V Sheehan Journal: Eat Weight Disord Date: 2016-03-04 Impact factor: 4.652